Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Kahla, Germany Clinical Trials

A listing of Kahla, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (33) clinical trials

Pomalidomide Ixazomib and Dexamethasone With or Without Intensification by Cyclophosphamide: A Study in Relapsed or Refractory Multiple Myeloma

The study is designed as an open-label, non-randomized, multicenter study to investigate the clinical activity of pomalidomide administered once daily in combination with oral ixazomib and dexamethasone (PId) until disease progression according to IMWG criteria. Patients with clinical relapse (any one of the following: deterioration of renal function, hypercalcemia, newly ...

Phase

6.16 miles

Learn More »

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

This is an investigational study, also known as LATTICE-CD, of the experimental medication BMS-986165 in participants with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

Phase

6.16 miles

Learn More »

KRT-232 in Subjects With PMF Post-PV MF or Post-ET MF Who Have Failed a JAK Inhibitor

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study is a global, open-label Phase 2 study to ...

Phase

6.16 miles

Learn More »

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with phlebotomy-dependent polycythemia vera (PV). Inhibition of MDM2 in PV is a new mechanism of action in PV. In Part A, patients must be resistant or intolerant to hydroxyurea or have undergone treatment ...

Phase

6.16 miles

Learn More »

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

This study is a multicenter, prospective phase II-study compares efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib. In this study will ...

Phase

6.16 miles

Learn More »

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Patients in Cohort A will be randomized 1:1 at the study entry to receive ADT (triptorelin + bicalutamide 50 mg) or standard chemotherapy. Patients of Cohort A randomized to the control arm (chemotherapy arm) will be given the option to enter Cohort B at the time of disease progression. As ...

Phase

6.16 miles

Learn More »

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the Phase Ib Study GA29469 and Phase II Study GA39925 (parent studies).

Phase

6.16 miles

Learn More »

Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

The purpose of this study is to assess the efficacy and safety of BMS-986165 in ulcerative colitis.

Phase

6.16 miles

Learn More »

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib Docetaxel or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

Phase

6.16 miles

Learn More »

Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24. Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.

Phase

6.16 miles

Learn More »